✦ LIBER ✦

Multitargeted Tyrosine Kinase Inhibitors in Unselected Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC): Impressions From MONET (the Motesanib NSCLC Efficacy and Tolerability Study)

✍ Scribed by Morgensztern, D.; Herbst, R. S.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of erlotinib in patients with a

✍ Michael BOYER; Keith HORWOOD; Nick PAVLAKIS; Paul DE SOUZA; Michael MILLWARD; Br 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

9165 Motesanib or bevacizumab in combina

✍ Blumenschein, G.; Schwartzberg, L.S.; Menon, H.; Mok, T.S.K.; Stephenson, J.J.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

1208 POSTER Phase I and Pharmacokinetic

✍ H. Yoshioka; I. Okamoto; K. Takeda; M. Satouchi; N. Yamamoto; T. Seto; K. Kasaha 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

9012 POSTER DISCUSSION A Phase lb Study

✍ Groen, H.; Adjei, A.A.; Dy, G.K.; Ware, J.A.; Shankar, G.; Brachmann, R.K.; Bess 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

6503 ORAL Efficacy and safety results fr

✍ Manegold, C.; vonPawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; Hirsh, V. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

68O EFFICACY, SAFETY AND TOLERABILITY RE

✍ Douillard, J.; Ostoros, G.; Cobo, M.; Ciuleanu, T.; McCormack, R.; Webster, A.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 45 KB